Neumora Therapeutics, Inc. (NMRA) on Monday announced positive results from a Phase 1b study of NMRA-511 in patients with agitation associated with Alzheimer's disease (AD).
The study evaluated NMRA-511 in healthy elderly participants and in patients with agitation related to dementia due to AD, and met its objectives of assessing clinical potential and informing further development. Neumora said the trial demonstrated a clinically meaningful and robust treatment effect across a broad patient population.
NMRA-511 produced a 15.7-point reduction in the mean Cohen-Mansfield Agitation Inventory (CMAI) total score, representing a clinically meaningful effect. The drug also showed an unsurpassed effect size in a pre-specified subgroup of patients with elevated anxiety and demonstrated a favorable safety and tolerability profile.
Based on the results, Neumora plans to initiate a multiple ascending-dose extension study of NMRA-511 in 2026 and to advance the drug into a Phase 2/3 dose-ranging study.
Neumora shares rose more than 10% in premarket trading after closing at $1.66 on Friday, down 7.3%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.